Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 1.00 |
| ▸ | TYK2 | P29597 | 3/20 | 1.00 |
| ▸ | JAK1 | P23458 | 2/20 | 1.00 |
| ▸ | JAK3 | P52333 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 10/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10191603 | 1.00 | JAK2 (1.00) | JAK2TYK2JAK1JAK3NTRK1 | |
| SCHEMBL401805 | 0.90 | TYK2 (0.82) | JAK2TYK2JAK1JAK3NTRK1 | |
| SCHEMBL405216 | 0.88 | TYK2 (0.79) | JAK2TYK2JAK1JAK3NTRK1 | |
| SCHEMBL13355519 | 0.85 | JAK2 (0.75) | JAK2TYK2JAK1JAK3PDE2A | |
| SCHEMBL15428573 | 0.85 | JAK2 (0.74) | JAK2TYK2JAK1JAK3PDE2A | |
| SCHEMBL401679 | 0.83 | JAK2 (0.71) | JAK2TYK2JAK1JAK3NTRK1 | |
| SCHEMBL402685 | 0.80 | JAK2 (0.67) | JAK2TYK2JAK1JAK3NTRK1 | |
| SCHEMBL15428681 | 0.79 | JAK2 (0.66) | JAK2TYK2JAK1JAK3IRAK4 | |
| SCHEMBL400798 | 0.78 | JAK2 (0.64) | JAK2TYK2JAK1JAK3NTRK1 | |
| SCHEMBL10191604 | 0.78 | JAK2 (0.64) | JAK2TYK2JAK1JAK3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885TYK2 18/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.